Following non-submission
AWMSG advice |
||
Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, lidocaine/prilocaine (Senstend®) cannot be endorsed for use within NHS Wales for the treatment of primary premature ejaculation in adult men |
||
|
||
Medicine details |
||
Medicine name | lidocaine / prilocaine (Senstend®) | |
Formulation | 150 / 50 mg/ml cutaneous solution | |
Reference number | 4384 | |
Indication | For the treatment of primary premature ejaculation in adult men |
|
Company | Plethora Solutions Holdings PLC | |
BNF chapter | Obstetrics, gynaecology & urinary tract disorders | |
Assessment type | Non-submission | |
Status | Not endorsed (Statement of Advice) | |
Date of issue | 16/06/2020 |